Literature DB >> 16143160

Recent updates on the role of chemotherapy in pancreatic cancer.

Howard A Burris1.   

Abstract

Single-agent gemcitabine remains the standard treatment for advanced pancreatic cancer. Recent phase III trials have failed to show improvements in survival using gemcitabine in combination with other chemotherapeutic agents, although the gemcitabine/oxaliplatin combination has shown some promise. The combination of gemcitabine with erlotinib was associated with a significant prolongation of survival. Promising results in a phase II trial of gemcitabine in combination with bevacizumab have led to a randomized comparative trial of the combination. Potential combinations with other biologic agents are being investigated.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16143160     DOI： 10.1053/j.seminoncol.2005.06.022

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


  22 in total

1.  The ARF tumor suppressor inhibits tumor cell colonization independent of p53 in a novel mouse model of pancreatic ductal adenocarcinoma metastasis.

Authors:  Viviane Palhares Muniz; J Matthew Barnes; Seema Paliwal; Xuefeng Zhang; Xiaoyun Tang; Songhai Chen; Kokou D Zamba; Joseph J Cullen; David K Meyerholz; Shari Meyers; J Nathan Davis; Steven R Grossman; Michael D Henry; Dawn E Quelle
Journal:  Mol Cancer Res       Date:  2011-06-02       Impact factor: 5.852

2.  Impact of APE1/Ref-1 redox inhibition on pancreatic tumor growth.

Authors:  Melissa L Fishel; Yanlin Jiang; N V Rajeshkumar; Glenda Scandura; Anthony L Sinn; Ying He; Changyu Shen; David R Jones; Karen E Pollok; Mircea Ivan; Anirban Maitra; Mark R Kelley
Journal:  Mol Cancer Ther       Date:  2011-06-23       Impact factor: 6.261

3.  Reduced expression of DNA repair and redox signaling protein APE1/Ref-1 impairs human pancreatic cancer cell survival, proliferation, and cell cycle progression.

Authors:  Yanlin Jiang; Shaoyu Zhou; George E Sandusky; Mark R Kelley; Melissa L Fishel
Journal:  Cancer Invest       Date:  2010-11       Impact factor: 2.176

4.  Longitudinal Bioluminescence Imaging of Primary Versus Abdominal Metastatic Tumor Growth in Orthotopic Pancreatic Tumor Models in NSG Mice.

Authors:  Harlan E Shannon; Melissa L Fishel; Jingwu Xie; Dongsheng Gu; Brian P McCarthy; Amanda A Riley; Anthony L Sinn; Jayne M Silver; Kacie Peterman; Mark R Kelley; Helmut Hanenberg; Murray Korc; Karen E Pollok; Paul R Territo
Journal:  Pancreas       Date:  2015-01       Impact factor: 3.327

5.  Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience.

Authors:  Christos Vaklavas; Apostolia-Maria Tsimberidou; Sijin Wen; David Hong; Jennifer Wheler; Chaan S Ng; Aung Naing; Cynthia Uehara; Robert A Wolff; Razelle Kurzrock
Journal:  Cancer       Date:  2010-08-24       Impact factor: 6.860

6.  Prolonged complete response following gemcitabine-erlotinib combined therapy in advanced pancreatic cancer.

Authors:  Anna M Czarnecka; Piotr Korzeń; Anna Nowak-Dement; Wojciech Kukwa; Jan Korniluk; Cezary Szczylik
Journal:  Oncol Lett       Date:  2015-12-07       Impact factor: 2.967

7.  Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study.

Authors:  Shimpei Maeda; Fuyuhiko Motoi; Tohru Onogawa; Takanori Morikawa; Ottomo Shigeru; Naoaki Sakata; Tatsuyuki Takadate; Takeshi Naitoh; Toshiki Rikiyama; Yu Katayose; Shinichi Egawa; Michiaki Unno
Journal:  Int J Clin Oncol       Date:  2011-04-01       Impact factor: 3.402

Review 8.  Selection criteria in resectable pancreatic cancer: a biological and morphological approach.

Authors:  Domenico Tamburrino; Stefano Partelli; Stefano Crippa; Alberto Manzoni; Angela Maurizi; Massimo Falconi
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

9.  Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model.

Authors:  C Bauer; F Bauernfeind; A Sterzik; M Orban; M Schnurr; H A Lehr; S Endres; A Eigler; M Dauer
Journal:  Gut       Date:  2007-03-29       Impact factor: 23.059

10.  Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer.

Authors:  John A Chabot; Wei-Yann Tsai; Robert L Fine; Chunxia Chen; Carolyn K Kumah; Karen A Antman; Victor R Grann
Journal:  J Clin Oncol       Date:  2009-08-17       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.